We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · July 01, 2022

Ranibizumab Via a Port Delivery System vs Intravitreal Injections in Patients With Neovascular AMD: Patient Preference and Treatment Satisfaction

JAMA Ophthalmology

 

Additional Info

JAMA Ophthalmology
Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol 2022 Jun 16;[EPub Ahead of Print], MA Chang, A Kapre, D Kaufman, DR Kardatzke, M Rabena, S Patel, A Bobbala, S Gune, A Fung, G Wallenstein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading